Entries Published On October, 2019
In this episode, Tobin and Dr. Ross sit down with Dr. Ronnie Mimran. Dr. Mimran is a graduate of UCLA and the USC Keck School of Medicine, and completed his neurosurgical residency and spine fellowship at the University of Florida. He earned his Cornell MBA in 2018. He is a board certified neurosurgeon in active practice in the Bay Area, and serves as the team neurosurgeon for the Oakland Raiders.
One of the greatest strengths of AngelMD comes from our pipeline of investment opportunities. Today we are sharing one of them with you. Each hand-picked Premium Syndicate offering must meet rigorous standards, but VICIS is one of the strongest offerings we’ve ever had. The AngelMD community has invested in this cutting-edge sports helmet company in the past, and we’re excited to offer an opportunity to be part of the VICIS success story.
The story of VICIS started at the University of Washington. Sam Browd, a Pediatric Neurosurgeon, believed that sports-related concussions and chronic traumatic encephalopathy (CTE) needed better solutions. Dr. Browd partnered with a leading engineer and an executive with extensive medical device experience to form VICIS.
For the past three years, VICIS has been named the safest helmet in football as measured by the NFL and the NFL Players Association. The company has 28 NFL teams, more than 200 NCAA programs and 1500 high school programs using its ZERO1 helmet this year.
The VICIS success story is evident through its sales. Demand for the ZERO1 helmet, and for forthcoming VICIS products continues to grow. The balance of 2019 will focus on football. In 2020, the company is launching into hockey with direct involvement from leaders like Wayne Gretzky and Brett Hull. The company also plans to expand into lacrosse, soccer, and even military applications. 2021 will begin the expansion into new categories.
This is a great opportunity to invest in a company and a product that is directly responsible for the first notable improvements in concussions and subsequent cases of CTE. This AngelMD Premium Syndicate is raising a minimum of $2 million in a convertible note in advance of a Series C round. To date the company has raised $85 million.
To learn more, and to start join this Syndicate, please click here.
Please invite your colleagues to become part of the AngelMD community. The more subject matter experts that we have participating on the platform, the more great opportunities like VICIS that we can bring to our members.